Cardinal Health
CAH
$200.68
+0.03%
Cardinal Health, Inc. is a leading healthcare services company operating primarily as one of the three dominant pharmaceutical wholesalers in the United States, alongside Cencora and McKesson. Its core business involves sourcing and distributing branded, generic, and specialty pharmaceutical products to a vast network of pharmacies, hospital networks, and healthcare providers, while also supplying medical-surgical products and equipment globally. The company's competitive identity is defined by its entrenched market position within a highly consolidated industry oligopoly, where it holds a significant share of the US pharmaceutical wholesale market. The current investor narrative is dominated by a mix of operational execution and market reaction, as evidenced by recent headlines where strong earnings beats and raised profit guidance were overshadowed by a sharp stock decline following a quarterly revenue miss, highlighting the market's intense focus on top-line growth in the face of the company's stable, low-margin distribution model.…
CAH
Cardinal Health
$200.68
Related headlines
Investment Opinion: Should I buy CAH Today?
Rating: Hold. The core thesis is that Cardinal Health is a stable, cash-generating defensive stock caught in a valuation tug-of-war between its strong market position and its low-margin, low-growth business model, making it suitable for income-oriented investors but offering limited near-term capital appreciation.
The Hold rating is supported by several specific data points. First, valuation is moderate but not compelling, with a forward P/E of 16.75x requiring successful execution on guidance. Second, while revenue growth was robust at 18.42% YoY, the recent sequential drop and miss signal volatility. Third, profitability is thin (net margin 0.72%) and inconsistent. Finally, analyst sentiment is bullish but provides no clear average target price to gauge implied upside, leaving the investment case reliant on the company hitting its own profit targets rather than a valuation discount.
The two biggest risks that could invalidate this Hold thesis are 1) a further deceleration in revenue growth or another significant miss, and 2) a failure to achieve the earnings implied by the forward P/E, leading to multiple compression. This Hold would upgrade to a Buy if the forward P/E compressed below 14x (aligning with historical lows) on sustained strong FCF generation, or if revenue growth stabilized above 15% with margin expansion. It would downgrade to a Sell if quarterly net income consistently fell below $400M or if the stock broke below key technical support near $183. Relative to its own history and the low-margin nature of its industry, the stock is currently fairly valued, not offering a clear margin of safety nor trading at an excessive premium.
Sign up to view all
CAH 12-Month Price Forecast
The AI assessment is neutral based on a balanced risk/reward profile. The company's entrenched market position and powerful cash generation are clear strengths, but they are counterbalanced by structural low margins, earnings volatility, and a weak balance sheet. The recent price decline reflects a market reassessment of growth expectations, moving the stock toward fair value. The stance would upgrade to bullish if the company demonstrates several quarters of stable revenue growth and margin expansion, proving it can consistently deliver on its guidance. Conversely, it would turn bearish on evidence of sustained margin erosion or a breakdown below key technical support, which could signal a fundamental deterioration in its competitive moat.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Cardinal Health's 12-month outlook, with a consensus price target around $260.88 and implied upside of +30.0% versus the current price.
Average Target
$260.88
6 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
6
covering this stock
Price Range
$161 - $261
Analyst target range
Analyst coverage for Cardinal Health is limited but consistent, with 6 analysts providing estimates. The consensus sentiment leans bullish, as evidenced by recent institutional ratings where firms like Barclays, Wells Fargo, Morgan Stanley, and Mizuho maintain 'Overweight' or 'Outperform' ratings, and Citigroup upgraded to 'Buy' in January 2026; however, the absence of a stated average target price in the data prevents calculation of a precise implied upside or downside from the current $200.68. The estimated EPS range for the forward period is tight, from $17.50 to $18.27, and the revenue estimate range is $332.94 billion to $344.22 billion; the high-end targets likely assume successful execution on raised profit guidance and stable market share, while the low-end may factor in ongoing margin pressures and competitive risks inherent in the wholesale distribution model. The pattern of recent analyst actions shows stability, with no downgrades in the provided data and several reiterations of positive ratings, suggesting institutional conviction in the company's fundamental outlook despite near-term stock price volatility.
Bulls vs Bears: CAH Investment Factors
The investment debate for Cardinal Health centers on the tension between its stable, cash-generating oligopoly business and its structurally low, volatile margins that limit earnings power. Currently, the bear case holds stronger near-term evidence, as the market has punished the stock for a revenue miss despite raised profit guidance, highlighting investor skepticism about sustainable growth in a low-margin model. The most critical factor is whether management can consistently deliver on its profit guidance to justify the forward P/E of 16.75x, or if margin pressures and revenue volatility will keep the stock range-bound. The strong analyst support and defensive beta provide a floor, but the weak balance sheet and recent technical breakdown present clear headwinds.
Bullish
- Strong Free Cash Flow Generation: The company generates substantial free cash flow, with TTM FCF of $5.51 billion. This provides significant financial flexibility to fund its dividend (payout ratio 31.6%), share buybacks, and strategic investments without straining its balance sheet.
- Dominant Market Position: Cardinal Health operates in a consolidated oligopoly, holding a significant share of the US pharmaceutical wholesale market alongside Cencora and McKesson. This entrenched position provides a stable, recurring revenue base, evidenced by quarterly revenue of $65.44 billion.
- Attractive Forward Valuation: The stock trades at a forward P/E of 16.75x, a significant discount to its trailing P/E of 25.94x. This implies the market expects strong earnings growth, aligning with management's raised profit guidance and analyst EPS estimates averaging $17.92.
- Analyst Conviction Despite Volatility: Analyst sentiment remains bullish, with six covering firms maintaining 'Overweight' or 'Buy' ratings, including a Citigroup upgrade in January 2026. This institutional conviction suggests confidence in the fundamental outlook despite the stock's recent 10.59% three-month decline.
Bearish
- Extremely Low and Volatile Margins: The company operates on razor-thin gross margins of 3.38% and a net margin of 0.72%. Profitability is inconsistent, with net income swinging from $506M to $239M in recent quarters, highlighting high sensitivity to operational costs in its low-margin distribution model.
- Recent Revenue Miss and Price Reaction: The stock sank sharply after its Q2 2026 revenue of $65.44B missed Wall Street expectations, overshadowing an earnings beat and raised guidance. This 14% decline from its 52-week high of $233.6 demonstrates the market's intense focus on top-line growth.
- Weak Balance Sheet with Shareholder Deficit: The company has a negative debt-to-equity ratio of -3.36, indicating a substantial shareholder deficit. While strong cash flow covers interest (coverage ratio 8.03), this leverage and negative equity signal financial fragility if operating performance deteriorates.
- High Revenue Concentration Risk: Growth is overwhelmingly dependent on the massive Pharmaceutical segment, which contributed $60.67B of the last quarter's $65.44B revenue. The minimal contributions from GMPD and Other segments expose the company to sector-specific risks within pharmaceutical distribution.
CAH Technical Analysis
The stock is currently in a pronounced downtrend from its recent highs, having declined 10.59% over the past three months and 4.20% over the past six months, which contrasts sharply with its strong 31.60% gain over the past year. Trading at a current price of $200.68, the stock sits approximately 54% above its 52-week low of $137.75 but 14% below its 52-week high of $233.6, indicating it has retreated significantly from peak levels and is now in a middle-ground position that suggests neither extreme momentum nor deep-value territory. Recent momentum has been decisively negative, with the stock down 10.59% over three months and showing a 1-month relative strength of -4.78 against the SPY, signaling significant underperformance and a clear deceleration from the longer-term uptrend; this divergence suggests the one-year rally has likely stalled, potentially entering a corrective or consolidative phase. Key technical support is anchored at the 52-week low of $137.75, while immediate overhead resistance is at the recent high of $233.6; a sustained breakdown below the $183-$185 area (recent lows) could accelerate selling toward the yearly low, whereas a recovery above $215-$220 is needed to signal trend stabilization. With a beta of 0.538, the stock exhibits roughly half the volatility of the broader market, which historically provides a defensive characteristic but also implies muted participation during strong market rallies, a factor crucial for risk-adjusted portfolio positioning.
Beta
0.54
0.54x market volatility
Max Drawdown
-20.6%
Largest decline past year
52-Week Range
$138-$234
Price range past year
Annual Return
+31.6%
Cumulative gain past year
| Period | CAH Return | S&P 500 |
|---|---|---|
| 1m | +0.1% | +4.4% |
| 3m | -10.6% | +9.3% |
| 6m | -4.2% | +10.5% |
| 1y | +31.6% | +28.8% |
| ytd | -2.4% | +9.3% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
CAH Fundamental Analysis
Revenue growth has been robust but shows signs of volatility, with the most recent quarterly revenue at $65.44 billion representing an 18.42% year-over-year increase; however, sequential trends reveal a drop from the prior quarter's $64.01 billion, and segment data indicates the massive Pharmaceutical Member segment ($60.67 billion) is the primary growth driver, while the smaller GMPD and Other segments contribute minimally to the top line. The company is profitable with net income of $471 million for the quarter and a net margin of 0.72%, but operates on razor-thin gross margins of 3.38%, which is characteristic of the low-margin distribution business; profitability has been inconsistent, with net income swinging from $506 million (Q3 2025) to $239 million (Q4 2025) in recent quarters, indicating sensitivity to operational costs and other expenses. The balance sheet shows significant financial leverage with a negative debt-to-equity ratio of -3.36, reflecting a substantial shareholder deficit, but the company generates strong operating cash flow ($686 million last quarter) and substantial trailing twelve-month free cash flow of $5.51 billion, providing ample internal funding for dividends, share buybacks, and acquisitions while covering interest expenses, as evidenced by an interest coverage ratio of 8.03.
Quarterly Revenue
$65.4B
2025-12
Revenue YoY Growth
+0.18%
YoY Comparison
Gross Margin
+0.03%
Latest Quarter
Free Cash Flow
$5.5B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is CAH Overvalued?
Given a positive net income of $471 million, the primary valuation metric is the Price-to-Earnings (PE) ratio. The stock trades at a trailing PE of 25.94x and a forward PE of 16.75x; the significant discount of the forward multiple implies the market expects substantial earnings growth in the coming year, likely pricing in the raised profit guidance management recently provided. Compared to sector averages, Cardinal Health's valuation is nuanced: its Price-to-Sales ratio of 0.18 is extremely low, typical for low-margin distributors, while its EV/EBITDA of 14.80x and forward PE of 16.75x are more meaningful benchmarks; without explicit industry averages in the data, the forward PE suggests a moderate valuation if earnings growth materializes as forecasted. Historically, the stock's own trailing PE has fluctuated widely, from a low near 14x (Q3 2025) to a high over 42x (Q4 2025); the current 25.94x sits above the middle of this recent range, indicating the market is not pricing in deep pessimism despite the recent price decline, but rather a normalization of expectations following the revenue miss.
PE
25.9x
Latest Quarter
vs. Historical
High-End
5-Year PE Range -450x~73x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
14.8x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks are pronounced, stemming from the company's inherently low-margin business model. Gross margins of 3.38% and net margins of 0.72% leave minimal room for error, making profits highly sensitive to cost inflation, competitive pricing, or supply chain disruptions. This is evidenced by volatile quarterly net income, swinging from $506M to $239M. Furthermore, the balance sheet shows significant leverage with a negative debt-to-equity ratio of -3.36, indicating a shareholder deficit. While strong operating cash flow ($686M last quarter) and FCF ($5.51B TTM) provide a cushion, any sustained compression in already-thin margins could quickly pressure the company's ability to service its obligations and maintain shareholder returns.
Market & Competitive Risks are anchored in valuation compression and sector dynamics. The stock's forward P/E of 16.75x, while a discount to its trailing multiple, still requires the company to hit raised profit targets. A failure to do so could trigger multiple contractions. As part of a consolidated oligopoly, the primary competitive threat is not new entrants but margin erosion from customer pressure (pharmacies, hospitals) or regulatory changes affecting drug pricing and distribution. The stock's low beta of 0.538 implies muted participation in market rallies, a risk for investors seeking growth. Recent news confirms the market's punitive reaction to revenue misses, indicating that stable cash flow is not enough to support the stock if growth narratives falter.
Worst-Case Scenario involves a combination of margin compression, failed guidance, and a loss of market confidence. Specifically, a sustained downturn in pharmaceutical volumes, coupled with increased competitive or customer pressure on distribution fees, could compress gross margins below 3%. This would lead to consecutive earnings misses, analyst downgrades from the current bullish stance, and a re-rating of the stock toward its historical low P/E near 14x. A realistic downside could see the stock retreat to its 52-week low of $137.75, representing a potential loss of approximately -31% from the current price of $200.68. The recent max drawdown of -20.61% shows the stock is susceptible to sharp declines when expectations are not met.
FAQ
The key risks are, in order of severity: 1) Margin Compression Risk: Gross margins of just 3.38% are highly vulnerable to cost inflation or customer pricing pressure, which could devastate net income. 2) Execution & Guidance Risk: The company must hit its raised profit targets to justify its forward P/E; another miss could trigger multiple contraction. 3) Financial Leverage Risk: The negative debt-to-equity ratio (-3.36) indicates a weak balance sheet structure, increasing vulnerability in a downturn. 4) Revenue Concentration Risk: Over 90% of revenue comes from the pharmaceutical wholesale segment, exposing the company to sector-specific regulatory and demand shocks. The recent stock price reaction to a revenue miss exemplifies the market's low tolerance for these risks.
The 12-month forecast for CAH is a range-bound outcome with a neutral bias. The base case (60% probability) sees the stock trading between $190 and $215 as it grinds through volatile quarterly results while meeting annual profit guidance. The bull case (25% probability) targets a return to the $233 high and beyond if execution is flawless and margins improve. The bear case (15% probability) warns of a decline toward the $138-$170 range if margins compress and earnings disappoint. The most likely scenario is the base case, which assumes the company's strong cash flow and market position provide a floor, but structural low margins cap significant upside. The key assumption is that management delivers EPS near the $17.92 analyst average.
CAH appears fairly valued relative to its business model and near-term prospects. The primary metric, forward P/E of 16.75x, represents a significant discount to the trailing P/E of 25.94x, implying the market expects solid earnings growth. Compared to its own history, where the P/E has ranged from ~14x to over 42x, the current multiple sits in a middle ground, suggesting neither deep pessimism nor excessive optimism. The extremely low Price-to-Sales ratio of 0.18 is typical for low-margin distributors and not a sign of undervaluation. Overall, the valuation implies the market is paying a fair price for expected profit growth but is not offering a clear margin of safety.
CAH is a conditional buy, primarily suitable for income-focused, defensive investors. Its attractiveness hinges on the current forward P/E of 16.75x, which prices in successful execution of management's raised profit guidance. The stock offers a modest 1.22% dividend yield supported by massive $5.51B annual free cash flow. However, the recent 10.59% three-month decline following a revenue miss highlights significant execution risk. It is a good buy for investors seeking a lower-volatility healthcare holding with stable cash returns, but not for those seeking high growth or a deep-value opportunity. A more attractive entry point might emerge if the stock tests support near $183.
CAH is more suitable for a long-term, buy-and-hold investment strategy rather than short-term trading. Its low beta (0.538) and stable, recurring revenue model from an oligopoly business are characteristics that compound value over time, primarily through dividend reinvestment. Short-term trading is challenged by the stock's low volatility and recent trend of underperforming the market (1-month relative strength -4.78%). Furthermore, earnings visibility is mixed due to quarterly profit volatility, making short-term predictions difficult. A minimum holding period of 3-5 years is suggested to ride out quarterly noise, collect dividends, and benefit from the company's entrenched market position and cash generation.